KR102120758B1 - Composition for preventing, ameliorating or treating allergic disease comprising coffee extract as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating an allergic disease containing a coffee residue extract as an effective component. The coffee residue ethanol extract reduces the amount of secretion of histamine after an increase in secretion from a mouse mast cell by compound 48/80 and reduces the amounts of generation of inflammatory chemokine (RANTES, TARC) and cytokine (IL-6) after an increase in secretion from a human skin keratinocyte (HaCaT cell) by TNF-α and IFN-γ. Especially, the coffee residue ethanol extract is more excellent in antihistamine and skin inflammation inhibitory activities than a coffee water extract or a coffee ethanol extract. Accordingly, the coffee residue ethanol extract of the present invention can be useful as a composition for preventing, ameliorating, or treating various allergic diseases such as edema, hypersensitivity, allergic dermatitis, contact dermatitis, atopic dermatitis, asthma, and hives.

Description

Composition for preventing, ameliorating or treating allergic disease comprising coffee extract as effective component containing coffee extract as an active ingredient

The present invention relates to a composition for preventing, improving or treating allergic diseases comprising coffee extract as an active ingredient.

Allergy is a malfunction of the immune system, which means that substances that have little effect on the average person cause abnormal hypersensitivity such as hives, itchiness, runny nose or cough in some people, and WHO is already the most problematic in the 21st century. Was included as the seventh disease. The main allergic diseases include atopic dermatitis, asthma, and rhinitis. Allergy is a disease close to incurable disease in modern medicine so far that there is no clear treatment. Antihistamines, which are not essential therapeutic agents in the treatment of allergic diseases, have excellent effects but use of steroids with many side effects make the disease worse and the economic burden of patients continues to increase.

In general, atopic symptoms or allergic diseases have been steadily increasing in the 21st century, accompanied by industrial development, westernization and instantiation of eating habits, serious environmental pollution, and new diseases such as sick house syndrome. The trend of developing allergic diseases is seriously occurring not only in Korea, but also in western societies, and even in many developing countries where development is in progress, so it is expected that these disease treatments will create global market demand.

Recently, as the prevalence of atopic dermatitis is rapidly increasing, the risk is greatly highlighted. As a kind of hypersensitivity, from an immunological point of view, the main symptoms are caused by immune reactions of immunoglobulin E and allergen. It is defined as a group of allergic diseases with strong genetic tendency.

Atopic dermatitis is a serious symptom in 0.5 to 1% of the population and 10 to 30% of children, but it is presumed to be related to genetic factors and immune system deficiency. It is expected to be somewhat relieved by improving the environment and diet, but there is no fundamental treatment. Although these atopic dermatitis have individual differences, most of them include skin irritation, rash, swelling, swelling, scaly skin (scales), including severe itching, and emotional anxiety, stress, tension, frustration, etc. Along with feelings of anger, it is frequently accompanied by other allergic diseases such as urticaria, metal allergy, asthma or allergic rhinitis, and is emerging as a serious social problem that threatens public health today. On the other hand, representative drugs that are known to be effective against atopic dermatitis to date include steroids, antihistamines, antibiotics, non-steroidal agents, and other sedatives and stabilizers.

Factors affecting the incidence of atopic dermatitis include air pollution, nuclear family, reduced breastfeeding, increased household income and education levels, increased exposure to antigens due to increased use of antibiotics, changes in the residential environment, and industrial development. Several factors are believed to be involved, including the emergence of new antigenic substances.

On the other hand, the allergic disease-related technology of the present invention discloses a cosmetic composition containing coffee silver skin extract as an active ingredient in Korean Registered Patent No. 1825704, and coffee fermented using Hongkukyun in Korean Registered Patent No. 1492174. A composition for anti-inflammatory and immuno-promoting comprising fermented green beans is disclosed, but a composition for preventing, improving or treating allergic diseases comprising the coffee residue extract of the present invention as an active ingredient has not been disclosed.

The present invention has been derived by the above-described needs, the present invention provides a composition for preventing, improving or treating allergic diseases comprising a coffee residue extract as an active ingredient, the active ingredient coffee of the present invention The residue ethanol extract (Coffee-R70E) is more than his water extract (Coffee-W) and coffee 70% (v/v) ethanol extract (Coffee-70E) histamine secretion, chemokine (RANTES) secretion and cytokine (IL-6) The present invention was completed by confirming that the effect of reducing the secretion amount was remarkable and that there was little cytotoxicity.

In order to achieve the above object, the present invention provides a health functional food composition for preventing or improving allergic diseases containing a coffee residue extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of allergic diseases containing a coffee residue extract as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing or improving allergic diseases comprising a coffee residue extract as an active ingredient.

In addition, the present invention provides a quasi-drug for the prevention or improvement of allergic diseases comprising a coffee residue extract as an active ingredient.

The present invention relates to a composition for preventing, improving or treating allergic diseases comprising a coffee residue extract as an active ingredient, wherein the coffee residue ethanol extract has increased secretion from mouse mast cells by compound 48/80. Lower the amount of histamine (histamine), increase the secretion from human skin keratinocytes (HaCaT cell) by TNF-α and IFN-γ, decrease the production of inflammatory chemokines (RANTES, TARC), cytokines (IL-6) It is effective.

Figure 1 is a high performance liquid chromatography (HPLC) of the coffee residue ethanol extract (Coffee-R70E) (A), coffee ethanol extract (Coffee-70E) (B) and coffee water extract (Coffee-W) (C) of the present invention It is an analysis result.
Figure 2 in mouse mast cells (A) and human keratinocytes (B), coffee water extract (Coffee-W), coffee 70% (v/v) ethanol extract (Coffee-70E) and coffee residue ethanol extract of the present invention It is the result of confirming the cytotoxicity of (Coffee-R70E).
3 is a result of confirming the histamine secretion amount of coffee water extract (Coffee-W), coffee 70% (v/v) ethanol extract (Coffee-70E) and coffee residue ethanol extract (Coffee-R70E) of the present invention.
Figure 4 is a coffee water extract (Coffee-W), coffee 70% (v / v) ethanol extract (Coffee-70E) and chemokine (RANTES) secretion according to the treatment of the coffee residue ethanol extract (Coffee-R70E) of the present invention It is the result of confirmation.
Figure 5 is a coffee water extract (Coffee-W), coffee 70% (v / v) ethanol extract (Coffee-70E) and chemokine (TARC) secretion according to the treatment of the coffee residue ethanol extract (Coffee-R70E) of the present invention It is the result of confirmation.
Figure 6 is a cytokine (IL-6) according to the treatment of coffee water extract (Coffee-W), coffee 70% (v/v) ethanol extract (Coffee-70E) and coffee residue ethanol extract (Coffee-R70E) of the present invention ) It is the result of checking the secretion amount.

The present invention relates to a health functional food composition for preventing or improving allergic diseases containing coffee residue extract as an active ingredient.

The allergic diseases include atopic dermatitis, allergic dermatitis, contact dermatitis, hives, itching, insect allergies, food allergy, drug allergies, edema, anaphylaxis, allergic rhinitis rhinitis), asthma (asthma) and allergic conjunctivitis (allergic conjunctivitis) is preferably any one selected from, but is not limited to.

The coffee residue extract is obtained by (1) pulverizing dry coffee, adding an extraction solvent, and repeating the removal of the supernatant 1 to 3 times to obtain a coffee residue; And (2) drying the coffee residue obtained in step (1), and then adding ethanol to the dried coffee residue to obtain a coffee residue extract; The extraction solvent of (1) is preferably selected from water, a lower alcohol of C ₁ to C ₄ or a mixture thereof, more preferably water, but is not limited thereto.

In the above production method, the extraction method of step (1) can use any conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux extraction and ultrasonic extraction. The extraction solvent of step (1) is preferably extracted by adding 1 to 20 times the weight of dry coffee powder, more preferably 5 to 15 times, and even more preferably 10 times. The extraction temperature is preferably 60 to 100°C, but is not limited thereto. Also, the total extraction time is preferably 1 to 48 hours, more preferably 1 to 24 hours, and most preferably 4 to 6 hours, but is not limited thereto.

The composition is preferably prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrups, and beverages, but is not limited thereto.

The health functional food composition of the present invention may be prepared by adding the coffee residue extract as it is or mixing it with other foods or food ingredients, and may be appropriately prepared according to a conventional method. Examples of foods to which the coffee residue extract can be added are caramel, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other dairy products including noodle, gum, ice cream, various soups, beverages, Tea, drink, alcoholic beverages and vitamin complexes may be in any one form, and includes all of the health functional foods in the usual sense. That is, there is no particular limitation on the type of food. The dietary supplement composition includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. It may also contain flesh for the preparation of natural fruit juices and vegetable drinks. The above components can be used independently or in combination. In addition, the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, and the natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, dextrin, and cyclo Polysaccharides such as dextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. The proportion of the natural carbohydrate is not critical, but for 100 g of the composition of the present invention, it is preferably 0.01 to 0.04 g, and more preferably 0.02 to 0.03 g, but is not limited thereto. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.

In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of allergic diseases containing a coffee residue extract as an active ingredient.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent. The pharmaceutically acceptable carrier contained in the pharmaceutical composition of the present invention is commonly used in the preparation, saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, lactose, and deck Strath, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrup, methyl cellulose, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like, but is not limited thereto. In addition, antioxidants, buffers, bacteriostatic agents, diluents, surfactants, binders, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents or preservatives may be further included in addition to the above components. The pharmaceutical composition of the present invention may be administered orally or parenterally, and parenteral administration may be administered by injection or application to the skin. When applied to the skin, it is preferred to use those prepared in the form of ointments, patches or sprays. Suitable dosages of the pharmaceutical compositions of the invention may be variously prescribed by factors such as formulation method, mode of administration, patient's age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion, and response sensitivity. Can be.

In addition, the present invention relates to a cosmetic composition for preventing or improving allergic diseases comprising a coffee residue extract as an active ingredient.

The cosmetic composition according to an embodiment of the present invention is a cream, soft cosmetic, nutrient cosmetic, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, Lotion, Milk Lotion, Moisture Lotion, Nutrition Lotion, Massage Cream, Nutrition Cream, Moisture Cream, Hand Cream, Foundation, Nutrition Essence, Sunscreen, Soap, Cleansing Foam, Cleansing Lotion, Cleansing Cream, Body Lotion and Body Cleanser It may have any one formulation selected from, but is not limited thereto. The cosmetic composition composed of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.

When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as carrier components Etc. can be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in the case of a spray, additionally chlorofluoro Propellants such as hydrocarbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, a solvating agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, and propylene Glycols, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspension agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.

When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate as a carrier component , Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linoline derivatives or ethoxylated glycerol fatty acid esters and the like.

The cosmetic composition of the present invention may further contain excipients including fluorescent materials, fungicides, oleogenic agents, moisturizers, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, sunscreens, vitamins, plant extracts, etc. .

In addition, the present invention relates to a quasi-drug for the prevention or improvement of allergic diseases comprising a coffee residue extract as an active ingredient.

The term'quasi-drug' in the present invention is a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a person or animal, and has a weak effect on the human body or does not act directly on the human body, Or a non-machine or similar product, one of the agents used for sterilization, pesticide and similar purposes to prevent infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases. Means of items that are not used as devices, machines or devices, and those used for purposes of pharmacologically affecting the structure and function of a person or animal, except those that are not devices, machinery or devices. In addition, the quasi-drug includes external skin preparations and personal hygiene products.

When the coffee residue extract of the present invention is used as a quasi-drug additive, the extract can be added as it is or used with other quasi-drugs or quasi-drug components, and can be suitably used according to a conventional method. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use. The external preparation for skin is not particularly limited thereto, but is preferably prepared and used in the form of ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. The personal hygiene products are not particularly limited, but preferably soap, cosmetics, wipes, tissues, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, makeup, foundation, ball touch, mascara, eye shadow, sunscreen It can be a lotion, a hair care product, an air freshener gel or a cleaning gel. In addition, another example of the quasi-drug composition of the present invention is a disinfecting cleaner, shower foam, green, wipes, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.

Hereinafter, the present invention will be described in more detail using examples. It is obvious to those skilled in the art that these examples are only intended to illustrate the present invention more specifically and that the scope of the present invention is not limited by them.

Example 1. Coffee Residue Preparation of extract

After crushing 200 g of dry coffee, 2 L of water was added, followed by reflux extraction (primary extraction) for 3 hours. The primary extract was filtered and 1 L of water was added again to the remaining residue, followed by reflux extraction (secondary extraction) for 1 hour, followed by filtration. The primary extract and the secondary extract were combined, concentrated and dried to prepare a coffee water extract (Coffee-W).

In the same manner, a 70% (v/v) ethanol solution was added to reflux extraction, filtration, concentration, and drying to prepare a coffee ethanol extract (Coffee-70E).

After the coffee water extract or the ethanol extract was obtained and the remaining coffee residue was dried, 1 L of 70% (v/v) ethanol was added to 50 g of the dried coffee residue, followed by reflux extraction for 3 hours. After filtering the extract, it was concentrated and dried to prepare an ethanol extract of coffee residue (Coffee-R70E).

As described above, the prepared coffee residue ethanol extract (Coffee-R70E), coffee ethanol extract (Coffee-70E) and coffee water extract (Coffee-W) were analyzed by HPLC (Charged Aerosol Detector) of HPLC. As a result, three new peaks were confirmed only in the ethanol extract of the coffee residue of the present invention in the 8 to 10 minutes (FIG. 1).

Example 2. Cultivation of mouse mast cells and human keratinocytes

MC/9 cells, mouse mast cells, were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin ), and cultured in a 37 °C, 5% CO ₂ environment with DMEM medium to which 100 μg/ml of streptomycin was added.

In addition, human keratinocyte HaCaT cells were added with 10% heat inactivated fetal bovine serum (FBS), 100 units/mL of penicillin, and 100 μg/mL of streptomycin with DMEM medium. And cultured in a 37°C, 5% CO ₂ environment.

Example 3. Coffee Residue Of extract Cytotoxicity check

In order to confirm the cytotoxicity of the coffee residue extract, a Cell Counting Kit-8 (CCK-8) assay was performed. MC/9 mast cells and HaCaT cells in 96-well plates were treated with samples (Coffee-W, Coffee-70E, Coffee-R70E) at concentrations (50, 100, 200 μg/ml), respectively, and cultured. After 24 hours, CCK-8 was added to the medium at a concentration of 10%, followed by reaction at 37°C for 2 hours. Thereafter, absorbance was measured at 450 nm using a microplate spectrophotometer (Biorad, Hercules, CA, USA), and relative cell viability (%) was calculated through comparison with a control group.

As a result, as shown in Fig. 2, mouse MC/9 mast cells and human keratinocytes, HaCaT cells, showed little cytotoxicity.

Example 4. Confirm the efficacy of suppressing histamine secretion

Inoculated cultured MC/9 mouse mast cells in a 96-well plate, 25 μg/ml compound 48/80 (Sigma, USA) and 50, 100 and 200 μg/ml samples (Coffee-W, Coffee-70E, Coffee) -R70E) for 30 minutes. Thereafter, the amount of allergic histamine secreted in the medium was measured with an ELISA kit (Oxford Biomedical Research Inc., USA). 100% production was calculated as the difference in the amount of histamine secretion between the untreated group and the untreated group. Histamine secretion (%) was calculated according to the following formula (1).

Formula (1): Histamine secretion (%) = [1-(Histamine secretion in the sample treatment group-Histamine secretion in the untreated group/Histamine secretion in the control group-Histamine secretion in the untreated group)]×100

As a result, as shown in Figure 3, the histamine secretion amount of the control group treated with Compound 48/80 was statistically significantly increased compared to the normal group (Cont) which did not process anything, but the coffee residue extract (Coffee-R70E) of the present invention ) Treated group showed a statistically significant decrease in histamine secretion compared to the compound 48/80 treated control group. In addition, it was further reduced compared to the coffee ethanol extract treatment group.

Example 5. Chemokine Secretion inhibition efficacy experiment

The cultured human keratinocytes (HaCaT cells) were inoculated into 6-well plates, and the samples were pre-treated at concentrations of 50, 100 and 200 µg/ml for 1 hour, followed by 10 ng/ml TNF-α and 10 ng/ml IFN. -γ was treated and incubated for 24 hours.

As a positive control, 12 and 25 µg/ml of silamarin were treated, respectively. After 24 hours, the secreted amount of chemokine (TARC, RANTES) and cytokine IL-6 secreted in the medium was measured with an ELISA kit (R&D systems Inc., Minneapolis, MN, USA). 100% activity was based on the difference in the amount of cytokine secretion between the untreated TNF-α and IFN-γ and the treated group.

As a result, as shown in FIGS. 4 to 6, the secretion amount of chemokine or cytokine of the control group treated with TNF-α and IFN-γ was statistically significantly increased compared to the normal group (Cont) which did not process anything, but In the group treated with the coffee residue extract (Coffee-R70E) of the present invention, the secretion amount of chemokine or cytokine was significantly reduced compared to the control group treated with TNF-α and IFN-γ. In addition, it was further reduced compared to the coffee ethanol extract treatment group.

All measurement results are expressed as mean and standard deviation (SD), and the difference between the experimental groups was statistically analyzed using Student's t-test and statistically significant when p <0.05. It was judged to be.

Claims (10)

(1) after pulverizing the dried coffee, after adding water, repeatedly removing the supernatant twice to obtain a coffee residue; And
(2) drying the coffee residue obtained in step (1), and then adding 70% (v/v) ethanol to the dried coffee residue to obtain a coffee residue extract; A health functional food composition for preventing or improving atopic dermatitis containing as an active ingredient. delete delete delete According to claim 1, wherein the composition is a health functional food composition for preventing or improving atopic dermatitis, characterized in that it is prepared in any one form selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage. (1) after pulverizing the dried coffee, after adding water, repeatedly removing the supernatant twice to obtain a coffee residue; And
(2) drying the coffee residue obtained in step (1), and then adding 70% (v/v) ethanol to the dried coffee residue to obtain a coffee residue extract; Pharmaceutical composition for the prevention or treatment of atopic dermatitis containing as an active ingredient. The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 6, further comprising a pharmaceutically acceptable carrier, excipient or diluent in addition to the coffee residue extract. The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 6, wherein the composition is a formulation of an ointment, patch or spray applied to the skin. (1) after pulverizing the dried coffee, after adding water, repeatedly removing the supernatant twice to obtain a coffee residue; And
(2) drying the coffee residue obtained in step (1), and then adding 70% (v/v) ethanol to the dried coffee residue to obtain a coffee residue extract; A cosmetic composition for preventing or improving atopic dermatitis comprising as an active ingredient. (1) after pulverizing the dried coffee, after adding water, repeatedly removing the supernatant twice to obtain a coffee residue; And
(2) drying the coffee residue obtained in step (1), and then adding 70% (v/v) ethanol to the dried coffee residue to obtain a coffee residue extract; A quasi-drug for the prevention or improvement of atopic dermatitis, which is included as an active ingredient.

Images